Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line.
about
Fluorescent derivatization of a protease antigen to track antigen uptake and processing in human cell linesRoles for major histocompatibility complex glycosylation in immune functionStructural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide bindingSelective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pHNitration of the pollen allergen bet v 1.0101 enhances the presentation of bet v 1-derived peptides by HLA-DR on human dendritic cellsHuman CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.Identification of a motif for HLA-DR1 binding peptides using M13 display librariesEmploying a recombinant HLA-DR3 expression system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a genetic, biochemical, and reverse immunological perspective.Truncation of the class II beta-chain cytoplasmic domain influences the level of class II/invariant chain-derived peptide complexes.High-throughput engineering and analysis of peptide binding to class II MHCA degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.Isolation of HLA-DR1.(staphylococcal enterotoxin A)2 trimers in solution.Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.Comparison of the secondary structures of human class I and class II major histocompatibility complex antigens by Fourier transform infrared and circular dichroism spectroscopyBinding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patientsPeptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding.Specificity and function of immunogenic peptides from the 35-kilodalton protein of Mycobacterium lepraeComplexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DMHLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.Cytolytic T lymphocytes from HLA-B8+ donors frequently recognize the Hodgkin's lymphoma associated latent membrane protein 2 of Epstein Barr virus.An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells.Staphylococcal enterotoxin A and toxic shock syndrome toxin compete with CD4 for human major histocompatibility complex class II binding.Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions.Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.Evidence for cobinding of self- and allopeptides to human class II major histocompatibility antigen DR1 by energy transfer.Expression of a class II major histocompatibility complex (MHC) heterodimer in a lipid-linked form with enhanced peptide/soluble MHC complex formation at low pH.Enhanced binding of peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH.Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant.Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM.Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models.Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic proteinSynergistic T cell activation via the physiological ligands for CD2 and the T cell receptor.Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II.Vaccinia peptides eluted from HLA-DR1 isolated from virus-infected cells are recognized by CD4+ T cells from a vaccinated donor.Zinc regulates the function of two superantigens.Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosisSpecific binding of antigenic peptides to separate alpha and beta chains of class II molecules of the major histocompatibility complex.Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II.
P2860
Q24804019-72BD22CD-85F8-4A75-B4CD-25A99684523DQ27013984-9295DD03-508E-469A-BAAC-5F07D97264E6Q28612873-6EF2C0B0-A80B-4264-9E0C-23320A3C8018Q28612958-6D5D6FC1-5C8F-4F2D-88EA-8032EB0A4FBFQ28732106-11CF4BF2-1198-4D47-B3CC-B18FB0F33BDBQ30442797-AEB49B7D-2C09-4CB8-A443-B69D51657F48Q33191162-0063BBE0-B4FE-4DB0-BD26-403793FA5B66Q33506224-939CEBD8-01A1-4F2E-ABD6-739FF514F9C6Q33613002-0E089716-BF33-4A9D-9088-BE229A6220F5Q33630225-1D2391D6-F6C8-45D6-BD65-5D5EE720B523Q33638509-84EB3592-CD85-4A92-95AE-D08AC8BB9FD0Q33651985-5DEABE06-BA52-4B9C-B31D-A2B006806498Q33839448-350B8640-2F82-46B7-991E-16D33764AE85Q33847346-18AC2A79-E8C6-4DF9-8A73-8F208AF2F939Q33890993-1DAF16BB-5E7A-42C1-895B-07FD365522BFQ33920167-6D77788F-FE22-42C4-BA3B-11571C06E468Q34000740-B6CEA5AB-9A09-4837-B941-723BB85F2324Q34083338-F367769E-DDFF-4ABB-B47B-080AD1A17D52Q34412690-D41E2BFF-0428-4AA2-800E-6DADF4FCC164Q34712758-F0687587-DDB6-4199-B4F6-4AD254423759Q35137191-7DB45251-C8AA-4FC7-9435-A3621B0D29B8Q35383132-05D52BC5-D949-4778-AC96-CAF1F982F4C7Q35815584-11D34EC6-ECCA-42B9-8502-A5AA17C6F2E3Q35839114-292B78D6-138F-453D-8D63-3DDC9BB8B172Q35890031-8921EF06-CC06-4162-ABD0-B57D19F29759Q36051669-B1A2D20C-E032-42CB-8738-499AB635BD57Q36230148-F9E7E5F5-5E62-4F6D-857B-761B7D0562B5Q36230523-4E52ACEB-8250-47EB-82B3-BECACE9923ABQ36230570-F18ED7CF-D003-4F32-9EF2-1B972ECEA361Q36241909-B8646517-2401-4EE0-996D-4C759CDF3FA7Q36288434-53B28E0B-B12D-4045-A4D4-86724F2D387CQ36322630-9561C681-32D2-44BD-9D61-615B2D02AEDFQ36355375-9CEA2962-5544-4B6F-9CFD-402F455E1AEDQ36361966-DE0CABFE-FB5D-460F-B280-033219A90488Q36364390-E405DE43-F05D-46C5-89C7-2A54907C4604Q36836183-35749034-D8CB-433C-AD91-9296827C6741Q37063096-A95A9948-2062-48A2-81C7-C6159C6D9541Q37381504-13489452-6CD5-45FF-A7D6-8B226DB689CFQ37666665-048D5EE6-B905-4031-A435-1AC60713639AQ39376188-79A70CFF-F2BE-4C55-B06D-E648B3DFDF56
P2860
Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Purification and characterizat ...... homozygous human B cell line.
@en
Purification and characterizat ...... homozygous human B cell line.
@nl
type
label
Purification and characterizat ...... homozygous human B cell line.
@en
Purification and characterizat ...... homozygous human B cell line.
@nl
prefLabel
Purification and characterizat ...... homozygous human B cell line.
@en
Purification and characterizat ...... homozygous human B cell line.
@nl
P2093
P1476
Purification and characterizat ...... homozygous human B cell line.
@en
P2093
Johnson DR
Raghupathy R
P304
16087-16094
P407
P577
1987-11-01T00:00:00Z